Catalog No.
YFJ70101
Expression system
E. coli
Species
Felis catus (Cat) (Felis silvestris catus)
Protein length
Phe19-Arg237
Predicted molecular weight
27.15 kDa
Nature
Recombinant
Endotoxin level
Please contact with the lab for this information.
Purity
>90% as determined by SDS-PAGE.
Accession
XP_006939101.1
Applications
ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress
Form
Lyophilized
Storage buffer
Lyophilized from a solution in PBS pH 7.4, 0.02% NLS, 1mM EDTA, 4% Trehalose, 1% Mannitol.
Reconstitution
Reconstitute in sterile water for a stock solution. A copy of datasheet will be provided with the products, please refer to it for details.
Shipping
In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Alternative Names
programmed cell death 1 ligand 1, CD274
PD-L1 expression in multiple myeloma myeloid derived suppressor cells., PMID:40180451
Immune checkpoint molecules performance in ANCA vasculitis., PMID:39537557
Cancer cell plasticity defines response to immunotherapy in cutaneous squamous cell carcinoma., PMID:38914547
CAR affinity modulates the sensitivity of CAR-T cells to PD-1/PD-L1-mediated inhibition., PMID:38670972
Performance of endobronchial ultrasound transbronchial needle aspiration as the first nodal staging procedure for the determination of programmed death ligand-1 expression in non-small cell lung cancer patients., PMID:37450028
Anticancer Effects of Thymoquinone through the Antioxidant Activity, Upregulation of Nrf2, and Downregulation of PD-L1 in Triple-Negative Breast Cancer Cells., PMID:36432484
NASH limits anti-tumour surveillance in immunotherapy-treated HCC., PMID:33762733
Circulating leukocyte-platelet complexes as a predictive biomarker for the development of immune-related adverse events in advanced non-small cell lung cancer patients receiving anti-PD-(L)1 blocking agents., PMID:33388994
Immunotherapy in NSCLC patients with brain metastases. Understanding brain tumor microenvironment and dissecting outcomes from immune checkpoint blockade in the clinic., PMID:32682248
Immune-related adverse events of checkpoint inhibitors., PMID:32382051
Multifunctional Immunoliposomes Combining Catalase and PD-L1 Antibodies Overcome Tumor Hypoxia and Enhance Immunotherapeutic Effects Against Melanoma., PMID:32214807
Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma., PMID:32173382
Immunotherapy for oncogenic-driven advanced non-small cell lung cancers: Is the time ripe for a change?, PMID:30359792
MET-Oncogenic and JAK2-Inactivating Alterations Are Independent Factors That Affect Regulation of PD-L1 Expression in Lung Cancer., PMID:29898990
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC., PMID:29863955
Immune checkpoint inhibitors in non-small cell lung cancer (NSCLC): Approaches on special subgroups and unresolved burning questions., PMID:29454155
Heterogeneity of Tumor and Immune Cell PD-L1 Expression and Lymphocyte Counts in Surgical NSCLC Samples., PMID:28549836
Genomic Profiling of Patient-Derived Xenografts for Lung Cancer Identifies B2M Inactivation Impairing Immunorecognition., PMID:28302866
FoxA1 directs the lineage and immunosuppressive properties of a novel regulatory T cell population in EAE and MS., PMID:24531377
For research use only. Not for human or drug use.
